Chatzipli, Aikaterini
Bonnefoi, Hervé http://orcid.org/0000-0003-4293-9748
MacGrogan, Gaetan
Sentis, Julie
Cameron, David
Poncet, Coralie
Abadie-Lacourtoisie, Sophie
Bodmer, Alexandre
Brain, Etienne
Cufer, Tanja
Campone, Mario
Luporsi, Elisabeth
Moldovan, Cristian
Petit, Thierry
Piccart, Martine
Priou, Franck
Senkus, Elsbieta
Zaman, Khalil
Iggo, Richard http://orcid.org/0000-0002-8822-9111
,
Funding for this research was provided by:
European Organisation for Research and Treatment of Cancer (EORTC) EBCC12
SIRIC-INCa-INSERM-DGOS 6046 Fondation pour la lutte contre le cancer et pour des recherches biologiques
Article History
Received: 25 November 2020
Revised: 4 July 2021
Accepted: 11 August 2021
First Online: 3 September 2021
Ethics approval and consent to participate
: The EORTC 10994 clinical trial was registered with ClinicalTrials.gov number NCT00017095 and approved by National and/or Local Ethics Committees in all participating centres. Before registration, all patients signed an informed consent for the trial and for mandatory p53 gene assessment on tumour samples. Patients involved in this substudy gave consent for additional biological research on their tumour samples. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: The authors declare no competing interests.